CNTB (Connect Biopharma Holdings) OCF Yield %: -38.21 (As of Jul. 01, 2026)


CNTB Connect Biopharma Holdings Ltd CNTB
7 GF Score
Price $2.38
! 3 Warning Signs
View Full Analysis

What is Connect Biopharma Holdings OCF Yield %?

Connect Biopharma Holdings CNTB +0.42% 7 OCF Yield % is -38.21 as of Jul. 01, 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Connect Biopharma Holdings ranks worse than 80.37% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Connect Biopharma Holdings's Trailing 12-Month Cash Flow from Operations is $-57.25 Mil, and Market Cap is $149.85 Mil. Therefore, Connect Biopharma Holdings's OCF Yield % for today is -38.21%.

The historical rank and industry rank for Connect Biopharma Holdings's OCF Yield % or its related term are showing as below:

CNTB' s OCF Yield % Range Over the Past 10 Years
Min: -50.92   Med: -39.59   Max: -24.96
Current: -38.21

During the past 7 years, the highest OCF Yield % of Connect Biopharma Holdings was -24.96%. The lowest was -50.92%. And the median was -39.59%.

CNTB's OCF Yield % is ranked worse than
80.37% of 1416 companies
in the Biotechnology industry
Industry Median: -8.185 vs CNTB: -38.21

Connect Biopharma Holdings's OCF Margin % for the quarter that ended in Mar. 2026 was %.

Connect Biopharma Holdings OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Connect Biopharma Holdings OCF Yield % Related Terms

Connect Biopharma Holdings OCF Yield % Historical Data

* Premium members only.

The historical data trend for Connect Biopharma Holdings's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings OCF Yield % Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -32.17

Connect Biopharma Holdings Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -82.65 -28.27 -38.96

CNTB vs ENLV, SMNR, MENS: OCF Yield % Comparison

For the Biotechnology subindustry, Connect Biopharma Holdings's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's OCF Yield % falls into.


CNTB
7GF Score
Connect Biopharma Holdings Ltd CNTB
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Connect Biopharma Holdings OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Connect Biopharma Holdings's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-51.206 / 159.16644
=-32.17%

Connect Biopharma Holdings's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-16.005 * 4 / 164.30544
=-38.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -38.21 mean?
Connect Biopharma Holdings (CNTB) has a OCF Yield % of -38.21 as of Jul. 01, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Connect Biopharma Holdings and its competitors. According to the industry distribution chart, Connect Biopharma Holdings ranks #1138 out of 1416 companies in the Biotechnology industry, placing it in the top 80.4%.
Is Connect Biopharma Holdings' OCF Yield % too high?
Connect Biopharma Holdings' current OCF Yield % is -38.21. Based on the distribution chart, Connect Biopharma Holdings ranks #1138 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' OCF Yield % compare to ENLV and SMNR?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #1138 out of 1416 companies for OCF Yield %. This places Connect Biopharma Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Connect Biopharma Holdings and its competitors. Connect Biopharma Holdings's current OCF Yield % is -38.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current OCF Yield % of -38.21. The current OCF Yield % is -38.21. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current OCF Yield % is -38.21 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Connect Biopharma Holdings Business Description

Address 3580 Carmel Mountain Road, Suite 200, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score

Get the complete analysis for CNTB

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.38
Price